Document is current
Any future updates will be listed below
-
Authors
van Wissen, Maria. A. T. https://orcid.org/0000-0002-2998-4256
van Weely, Salima F. E. https://orcid.org/0000-0001-8560-4687
van den Ende, Cornelia. H. M. https://orcid.org/0000-0002-4352-2824
Vliet Vlieland, Theodora P. M. https://orcid.org/0000-0001-6322-3859
Teuwen, Max M. H. https://orcid.org/0000-0002-3235-7800
Peter, Wilfred. F. https://orcid.org/0000-0003-1456-2429
Mahler, Eline A. M. https://orcid.org/0000-0002-6833-3157
van Schaardenburg, Dirkjan https://orcid.org/0000-0003-4006-3762
van Gaalen, Floris https://orcid.org/0000-0001-8448-7407
Spoorenberg, Johanna P. L. https://orcid.org/0000-0001-8850-8578
van Tubergen, Astrid M. https://orcid.org/0000-0001-8477-0683
Gademan, Maaike G. J. https://orcid.org/0000-0002-6106-3385
van den Hout, Wilbert B. https://orcid.org/0000-0002-6425-0135
-
Funding
Funding for this research was provided by:
ZonMw NL (852004019)
Ministry of Health, Welfare and Sport (Ministry of Health, Welfare and Sport (Ministerie van Volksgezondheid, Welzijn en Sport))
Koninklijk Nederlands Genootschap voor Fysiotherapie (Koninklijk Nederlands Genootschap voor Fysiotherapie)
Dutch Arthritis Association (Dutch Arthritis Association)
- License Information
-
More Information
Article History
Received: 6 January 2026
Accepted: 16 May 2026
First Online: 5 June 2026
Declarations
:
: M.A.T van Wissen, S. F.E. van Weely, C.H.M. van den Ende, T.P.M. Vliet Vlieland, M.M.H Teuwen, W.F. Peter, E.A.M. Mahler, D. van Schaardenburg, J.P.L. Spoorenberg, M. G.J. Gademan, and W.B. van den Hout declare that they have no known conflicts of interest. Astrid M. van Tubergen received speaker fees from Pfizer and Novartis; consulting fees from Abbvie, Novartis, Johnsson and Johnson, and UCB; and unrestricted research grants from Abbvie, UCB, and Novartis. F. van Gaalen is member of the ASAS Executive Committee and ASAS treasurer and received grants from Stichting Vrienden van Sole Mio and Stichting ASAS and fees/contracts from AbbVie, Novartis, UCB, Alfasigma, Johnson&Johnson, Lilly, Merck, and Pfizer with all payments made to employer (LUMC, full time contract).
: The study was approved by the Medical Ethical Review Board Leiden-Delft-Den Haag on July 11, 2019 (METC-LDD, NL70093.058.19, ).
: This report was not prearchived in a local repository.
: The results of this economic analysis have not been previously presented as an abstract.
